TriReme Medical is a California medical device firm with offices in Singapore that develops minimally invasive coronary and peripheral devices. Its product lineup includes the Chocolate, GliderXtreme and GliderfleX PTA balloon catheters for peripheral use and the Antares Coronary Stent system and Glider PTCA balloon catheters for coronary procedures. The company focuses on treating complex lesions and advancing next-generation interventional devices. TriReme will use the new funding to support development of its dilation catheters and to expand its commercial infrastructure globally. The company’s board includes representatives from Adams Street Partners, Three Arch Partners, Bio*One Capital and EDB Investments. CEO Eitan Konstantino said the company is "thrilled to have this major support from Asia" as it advances its device development. TriReme Medical develops, manufactures and commercializes percutaneous devices to treat complex coronary and peripheral arterial disease. The company is based in Pleasanton, California and its portfolio includes two CE marked products: the Antares® Coronary Stent System and the Glider™ PTCA Balloon Catheter. Antares is a proprietary main vessel stent designed to adapt to a broad variety of bifurcation lesions for predictable provisional stenting results. The Glider PTCA Balloon Catheter is designed to overcome limitations of conventional balloon catheters when treating complex disease. TriReme intends to use new capital to ramp up worldwide commercial activities and continue internal R&D programs. Management also plans to pursue key regulatory approvals in large markets including the US, Japan and China.

Total raised

$35M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2012